

Full Optimisation.

Three months. Your biology, tracked.

133 markers · Bloodwork integration · 3 monthly protocol reviews · Written Q&A; each month

Prepared for

Programme Start

Platform

L.M.

August 2026

23andMe v5

Sample report — anonymised. Educational purposes only. Does not constitute medical advice.

Three months. One structured system. Your protocol moves with your biology.

The Full Optimisation programme is not a report you read once. It is a structured 90-day system — your genetics and bloodwork are the foundation, and each month the protocol is updated based on new data you submit. No open inbox. No reactive messaging. A system that is intentional, data-driven, and compounds over time.

MONTH 1 — Foundation

Report delivery	133-marker DNA analysis + bloodwork integration. Root Cause Summary. Full supplement protocol with research doses, drug interactions, and supplement stack review.
Written Q&A; session	Submit your questions after reading the report. Receive written answers within the week.
Month 1 intake form	Sent at end of Month 1. Covers bloodwork, supplement response, symptom changes.
Protocol revision	Based on Month 1 intake. Your protocol is updated and delivered.

MONTH 2 — Adjustment

Month 2 intake form	New bloodwork encouraged. Supplement response and any symptom changes documented.
Written Q&A; session	Second Q&A; — questions become more specific as the protocol progresses.
Protocol revision	Updated based on Month 2 data. Each revision builds on what has been confirmed working.

MONTH 3 — Optimisation

Month 3 intake form	Final intake. Blood markers compared to baseline. 90-day response data reviewed.
Written Q&A; session	Third Q&A; session — at 90 days the picture is substantially clearer.
Final protocol + 90-day summary	Updated protocol and summary of what changed, what moved, what the next phase should address.

What Your Biology Has Been Trying to Tell You.

CAUSES IDENTIFIED

- 1 **CYP1B1 + ESR1 oestrogen metabolism** — your body processes oestrogen through a pathway that generates more inflammatory metabolites — a driver of hormonal fluctuation and tissue sensitivity that has not responded to standard approaches.
- 2 **MTHFR C677T heterozygous + elevated hsCRP** — methylation capacity is reduced and systemic inflammation is measurable. Impaired methylation reduces the body's ability to clear the pro-inflammatory oestrogen metabolites that CYP1B1 generates.
- 3 **IL-6 GG variant** — your immune system runs at a higher baseline inflammatory tone. Combined with the oestrogen metabolism picture, chronic low-grade inflammation is structurally predicted by this variant panel.
- 4 **Suboptimal ferritin, Vitamin D, and hsCRP** — the biomarker picture confirms what the genetics predict. These are downstream expressions of the same underlying mechanisms.

YOUR PATH FORWARD

- *DIM + calcium-d-glucarate* — oestrogen metabolite clearance via 2-OH pathway
- *Active folate* — methylation support timed to menstrual cycle phase
- *Omega-3 + curcumin* — IL-6 pathway modulation
- *Ferritin and Vitamin D* — functional targets specific to this panel
- *Monthly tracking* — each update monitors which interventions are shifting the picture

Your complete Path Forward — supplement forms, research doses, cycle-synced timing, and the reasoning behind every decision — is in your full report.

MONTH 2 PROTOCOL UPDATE — SAMPLE

This is what a monthly protocol update looks like at Month 2. The intake form has been completed, new bloodwork submitted, and this is the revised protocol with the reasoning behind each change.

MONTH 2 INTAKE SUMMARY

Ferritin: 52 µg/L (was 31) · Vitamin D: 78 nmol/L (was 48) · hsCRP: 1.4 mg/L (was 2.1)

Supplement response: DIM tolerated well. Active folate started at 400 mcg — no adverse reaction. Omega-3 added Week 3. Energy improvement noted. Bloating persists mid-cycle.

PROTOCOL CHANGES — MONTH 2

CONTINUE	DIM — continue	Ferritin moving (31→52) and hsCRP improving (2.1→1.4). Protocol is working. Continue current dose. Recheck Month 3.
ADJUST	Active folate — increase to 600 mcg	No accumulation symptoms at 400 mcg across 6 weeks. MTHFR CT heterozygous allows higher ceiling than TT. Increase with morning largest meal.
NEW	Add calcium-d-glucarate 500 mg	Mid-cycle bloating consistent with Phase 2 oestrogen clearance insufficiency. Inhibits beta-glucuronidase, reducing oestrogen reabsorption. Timing: Day 14-28, with food.
ADJUST	Omega-3 — confirm form and increase	For CYP1B1 profile, EPA-dominant ratio preferred. If ethyl ester, switch to triglyceride form. Target: 2g EPA + 1g DHA daily.

Month 2 Q&A,: submitted questions answered in writing within the week. Month 3 intake form sent at start of next month.

Your results came back normal. You still don't feel normal.

Three tiers. One biological picture.

Tier 1 DNA Blueprint	Tier 2 Blueprint + Bloodwork	Tier 3 Full Optimisation
\$397	\$697	\$1,197
✓ 133 markers · 12 domains ✓ Root Cause Summary ✓ SNP interaction analysis ✓ Supplement protocol + doses ✓ Drug-supplement interactions ✓ Supplement stack review ✓ Food guidance ✓ 90-day plan ✓ Peer-reviewed citations — No bloodwork — No Q&A; — No updates	✓ Everything in Tier 1 ✓ Bloodwork vs functional ranges ✓ Biomarker Snapshot ✓ Written Q&A; session — No monthly updates	✓ Everything in Tier 2 ✓ 3-month programme ✓ Monthly intake form ✓ Monthly protocol revision ✓ Monthly written Q&A; ✓ 90-day summary report The data compounds.